
Erasca, Inc. (NASDAQ:ERAS – Free Report) – Equities researchers at HC Wainwright dropped their FY2026 earnings estimates for Erasca in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.54) per share for the year, down from their previous estimate of ($0.51). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Erasca’s Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.88) EPS.
Erasca (NASDAQ:ERAS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
A number of other analysts have also recently weighed in on ERAS. Guggenheim raised their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Morgan Stanley upped their price target on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research report on Tuesday, September 8th. Finally, Bank of America increased their price objective on Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.09.
Read Our Latest Stock Report on ERAS
Erasca Price Performance
ERAS stock opened at $15.11 on Tuesday. Erasca has a 12 month low of $2.52 and a 12 month high of $24.28. The firm has a market cap of $5.28 billion, a PE ratio of -15.26 and a beta of 0.68. The firm has a 50 day simple moving average of $14.94 and a 200 day simple moving average of $15.28.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wealthcare Advisory Partners LLC increased its stake in Erasca by 5.0% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 15,924 shares of the company’s stock valued at $292,000 after buying an additional 756 shares during the period. Nykredit A S purchased a new stake in Erasca in the 2nd quarter worth approximately $29,000. Allworth Financial LP acquired a new stake in shares of Erasca during the 2nd quarter valued at $34,000. EverSource Wealth Advisors LLC boosted its stake in shares of Erasca by 77.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock valued at $69,000 after buying an additional 1,859 shares during the period. Finally, ProShare Advisors LLC grew its holdings in shares of Erasca by 9.3% during the 3rd quarter. ProShare Advisors LLC now owns 39,799 shares of the company’s stock valued at $583,000 after acquiring an additional 3,391 shares in the last quarter. 67.78% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about Erasca
Here are a few of the latest headlines about ERAS:
- Positive Sentiment: Erasca will host a November 20 investor event to discuss updated Phase 1 results for ERAS-0015. The company has reported early favorable safety and tolerability, along with partial responses in multiple tumor types, including at low doses. Further clinical details could be a catalyst, though these are preliminary findings. Erasca Announces Virtual Investor Event
- Positive Sentiment: HC Wainwright retained its Buy rating and $22 price target. The firm’s outlook may help temper concerns about the company’s near-term losses.
- Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for 2026 through 2030, including FY2027 from $0.58 to $0.90 and FY2029 from $0.70 to $1.07. The revisions suggest greater anticipated losses and could weigh on sentiment, despite the continued Buy rating.
About Erasca
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Featured Articles
- Five stocks we like better than Erasca
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
